UNITED THERAPEUTICS Corp
For the period ended Jun 30, 2025. Filed Jul 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 30, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)Trading Plans
On May 2, 2025, Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 294,000 stock options and sell the shares of our common stock received, subject to certain conditions. These stock options expire in March 2026.
On June 3, 2025, trusts beneficially owned by Michael Benkowitz, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 576,940 stock options and sell the shares of common stock received, subject to certain conditions. These stock options expire in March 2027.
During the three months ended June 30, 2025, no director or Section 16 officer terminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).
| Quarterly Report | 55 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.